INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Weight & Appetite desk →

1,735 studies · page 49 of 73

2025 / Randomized controlled trial

A whole-food, plant-based diet with exercise improved glycaemic control and reduced medication use in individuals with type 2 diabetes.

In a 24-week parallel-arm randomized trial, 169 adults with type 2 diabetes were assigned to an intensive whole-food, plant-based intervention with moderate exercise (PB+Ex) or standard medical care (SMC). Compared with SMC, the PB+Ex intervention resulted in greater HbA1c reductions at week 12 (-22 vs -7 mmol/mol [-2.0% vs -0.7%]; p<0.0001) and week 24 (-16 vs -8 mmol/mol [-1.4% vs -0.7%]; p=0.01). Furthermore, 63% of medicated PB+Ex participants reduced glucose-lowering medications compared to 24% in SMC (p=0.006), and 23% with baseline HbA1c <75 mmol/mol achieved remission. PB+Ex also led to reductions in weight (-2.7 kg; p<0.0001), C-reactive protein (-11 nmol/l; p=0.005), and cardiovascular medication use.

Hanick CJ, Peterson CM, Davis BC, et al. Diabetologia, 2025. PMID 39305340

2024 / Phase 3, randomized withdrawal clinical trial

Continued treatment with tirzepatide maintained and further reduced weight, whereas switching to placebo led to substantial weight regain.

In this phase 3 trial, 783 adults completed a 36-week open-label tirzepatide lead-in period with diet and physical activity, achieving a mean weight reduction of 20.9%. At week 36, 670 participants were randomized to continue tirzepatide or switch to placebo for 52 weeks. Mean percent weight change from week 36 to 88 was -5.5% with tirzepatide compared to +14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001). Overall, 89.5% of tirzepatide participants maintained at least 80% of initial weight loss versus 16.6% on placebo. The most common adverse events were mostly mild to moderate gastrointestinal symptoms.

Aronne LJ, Sattar N, Horn DB, et al. JAMA, 2024. PMID 38078870

2024 / Randomized controlled trial (ancillary analysis)

Prune supplementation for 12 months did not alter glycemic markers or blood lipids in postmenopausal women, and may prevent adverse changes in central adiposity.

An ancillary study of a 12-month RCT evaluated the effects of 50 g/day or 100 g/day prune supplementation compared with a control group in postmenopausal women. Neither 50 g/day nor 100 g/day prunes altered markers of glycemic control or blood lipids after 12 months (all P > 0.05), nor did gynoid percent fat and visceral adipose tissue indices differ significantly between groups. However, android total mass increased by 3.19% ± 5.5% from baseline in the control group, whereas it decreased by 0.02% ± 5.6% in the 100 g/d group (P < 0.01).

Damani JJ, Rogers CJ, Lee H, et al. J Nutr, 2024. PMID 38490532

2024 / Double-blind randomized controlled trial

Curcumin supplementation (500 mg/d for 24 weeks) significantly reduced hepatic fat content, weight, and glycemic markers in patients with NASFL.

In a 24-week double-blind randomized trial, 80 patients with NASFL were assigned to 500 mg/day curcumin or placebo. Compared with placebo, curcumin significantly reduced controlled attenuation parameters (-17.5 dB/m; P < 0.001), body weight (-2.6 kg; P < 0.001), BMI (-1.0 kg/m2; P = 0.032), free fatty acids, triglycerides, fasting blood glucose, HbA1c, and insulin. Curcumin also decreased the Firmicutes to Bacteroidetes ratio, increased Bacteroides abundance, elevated serum deoxycholic acid and glucagon-like peptide-1, and increased TGR5 expression.

He Y, Chen X, Li Y, et al. Am J Clin Nutr, 2024. PMID 38795741

2023 / Randomized controlled trial

Dietary and physical activity interventions reduced body weight and alleviated tinnitus symptoms in obese adults.

Sixty-three obese adults with tinnitus were randomized into diet + physical activity (n=15), diet (n=16), physical activity (n=15), or control (n=17) groups. Body weight decreased significantly in the diet + physical activity (-5.9 (3.5) kg), diet (-3.4 (0.9) kg), and physical activity (-2.0 (2.1) kg) groups compared to baseline (p < 0.05). Participants achieving ≥5.0% weight loss experienced greater reductions in tinnitus frequency, severity, and VAS scores than those with <5.0% weight loss (p < 0.05). Each 1 kg/m2 decrease in BMI reduced the BDI score by 0.485 units and the THI score by 0.523 units, while each 1,000-step increase decreased the THI score by 0.750 units and increased the SF-36 score by 1.592 units.

Özbey-Yücel Ü, Uçar A, Aydoğan Z, et al. Auris Nasus Larynx, 2023. PMID 35568580

2023 / Parallel-arm, assessor-blind randomized controlled trial

A 16-week multidisciplinary lifestyle program with a whole-food plant-based diet reduced disease activity in patients with rheumatoid arthritis.

In the 'Plants for Joints' trial, 83 patients with rheumatoid arthritis and low-to-moderate disease activity were randomized to a 16-week lifestyle program (whole-food plant-based diet, physical activity, and stress management) or usual care. After 16 weeks, the lifestyle group achieved a 0.9-point greater improvement in DAS28 compared to control (95% CI 0.4, 1.3; P < 0.0001). The intervention also led to greater decreases in body weight (-3.9 kg), fat mass (-2.8 kg), waist circumference (-3 cm), HbA1c (-1.3 mmol/mol), and LDL cholesterol (-0.32 mmol/l), with no changes observed in patient-reported outcomes, blood pressure, glucose, or other lipids.

Walrabenstein W, Wagenaar CA, van der Leeden M, et al. Rheumatology (Oxford), 2023. PMID 36617162

2023 / Double-blind randomized crossover study

Enriching white bread with cellular chickpea flour increased satiety-promoting gut hormones and reduced postprandial glycemia in healthy adults.

In a double-blind randomized crossover study, 20 healthy participants consumed white bread enriched with 0%, 30%, or 60% cellular chickpea powder (CCP). Bread type significantly altered postprandial GLP-1 and PYY responses (both P = 0.001); 60% CCP bread produced significantly higher iAUCs for GLP-1 (mean difference 3101 pM/min; 95% CI: 1891, 4310) and PYY (mean difference 3576 pM/min; 95% CI: 1024, 6128) compared with 0% CCP, and tended to increase fullness (P = 0.053). Additionally, bread type significantly influenced glycemia and insulinemia, with 30% CCP bread resulting in a >40% lower glucose iAUC (P-adjusted < 0.001) than the 0% CCP bread.

Bajka BH, Pinto AM, Perez-Moral N, et al. Am J Clin Nutr, 2023. PMID 36811474

2023 / Randomized controlled trial

A Nordic, protein-reduced complementary diet increased fruit and vegetable intake and lowered protein intake and IGF-1 in infants without altering growth.

Healthy, term infants (n = 250) were randomized to follow either a Nordic complementary diet (NG) with Nordic taste portions, recipes, and protein-reduced products, or standard Swedish dietary recommendations (CG) from complementary feeding up to 18 months. Of the participants, 82% (n = 206) completed the trial. There were no differences between groups in body composition, growth, energy intake, or iron status. However, NG had lower protein intake, blood urea nitrogen, and plasma IGF-1, while consuming 42% to 45% more fruits and vegetables and displaying higher plasma folate at 12 and 18 months compared to CG.

Johansson U, Öhlund I, Lindberg L, et al. Am J Clin Nutr, 2023. PMID 36990225

2023 / Randomized controlled trial

A 16-week plant-based diet, exercise, and stress-reduction program significantly improved WOMAC scores and metabolic markers in metabolic syndrome osteoarthritis.

Sixty-six patients with hip or knee metabolic syndrome-associated osteoarthritis were randomized to a 16-week multidisciplinary lifestyle program (whole food plant-based diet, physical activity, stress management) plus usual care, or usual care alone. After 16 weeks, the intervention group had an 11-point larger improvement in WOMAC score compared to controls (95% CI 6-16; p = 0.0001). The intervention group also lost more weight (-5 kg), fat mass (-4 kg), and waist circumference (-6 cm), and had greater improvements in PROMIS fatigue, pain interference, CRP, HbA1c, fasting glucose, and LDL.

Walrabenstein W, Wagenaar CA, van de Put M, et al. Osteoarthritis Cartilage, 2023. PMID 37328047

2023 / Randomized controlled trial

Cinchona supplementation combined with a hypocaloric diet promoted significant improvements in body composition and weight loss in overweight/obese adults.

Fifty-nine overweight/obese adults were randomized to receive a hypocaloric diet plus Cinchona succirubra supplementation (n=32) or a hypocaloric diet plus placebo (n=27) for 2 months. Anthropometric measurements, bioimpedance analysis, a Zung test, and biochemical parameters were evaluated at baseline and after 60 days. Adults in the cinchona group showed significant improvements in nutritional status and body composition compared to baseline and the placebo group, and did not show a reduction in serum cholecystokinin levels compared to placebo.

Chiurazzi M, De Conno B, Di Lauro M, et al. Nutrients, 2023. PMID 38140292

2022 / 4-arm randomized controlled trial

Early vegetable-exposure and sensitive-feeding interventions did not increase child vegetable intake or self-regulation of energy intake at 18 or 24 months.

A 4-arm randomized controlled trial evaluated repeated vegetable exposure (RVE), sensitive feeding (VIPP-FI), a combination (COMBI), and an attention control (AC) among 246 mother-infant pairs from age 4-6 months to 16 months. At follow-ups (18 and 24 months), no group differences were found for child vegetable intake or self-regulation of energy intake. Overweight prevalence was lower in the COMBI group versus VIPP-FI at 18 months (2% vs. 16%) and versus AC at 24 months (7% vs. 20%), though continuous BMI z-scores showed no significant differences (P = 0.29-0.82). More sensitive feeding and less pressure to eat were observed in the VIPP-FI and COMBI groups compared to RVE and AC, primarily at 18 months (d = 0.23-0.64).

van Vliet MS, Schultink JM, Jager G, et al. J Nutr, 2022. PMID 34791320

2022 / Randomized, double-blind, 3-treatment crossover trial

A bitter hop extract delivered to the stomach or duodenum reduced acute ad libitum energy intake and altered gut peptide hormones in healthy-weight men.

Nineteen healthy-weight men participated in a double-blind, 3-treatment crossover study receiving placebo or 500 mg hop extract via delayed-release (duodenal) or quick-release (gastric) capsules. Compared with placebo (5383 kJ; 95% CI: 4722, 6045), total ad libitum energy intake decreased following both gastric (4473 kJ; 95% CI: 3811, 5134; P = 0.006) and duodenal (4439 kJ; 95% CI: 3777, 5102; P = 0.004) delivery. Hop treatments stimulated prelunch ghrelin and postprandial CCK, GLP-1, and PYY, but reduced postprandial insulin, GIP, and pancreatic polypeptide without affecting glycemia. Small increases in gastrointestinal discomfort occurred with both hop treatments, including mild to severe symptoms in the gastric group, with no significant effects on subjective appetite ratings.

Walker EG, Lo KR, Pahl MC, et al. Am J Clin Nutr, 2022. PMID 35102364

2022 / Randomized controlled trial

Consuming 40 g of brown or golden flaxseed daily for 12 weeks reduced intestinal permeability and endotoxemia in perimenopausal overweight women.

Thirty perimenopausal overweight women were divided into a control group, brown flaxseed group, and golden flaxseed group, with the intervention groups consuming 40 g of flaxseed daily for 12 weeks. Intestinal permeability was significantly reduced in the flaxseed groups, with a smaller delta of lactulose/mannitol ratio (p ≤ 0.05). LPS levels were reduced in both flaxseed groups, while LDL decreased in the golden flaxseed group (p ≤ 0.05). Flaxseed consumption did not change oxidative stress markers or fasting glycaemia.

Sant'Ana CT, Amorim AD, Gava AP, et al. Int J Food Sci Nutr, 2022. PMID 35311432

2022 / Randomized controlled trial extension

One year after stopping semaglutide and lifestyle intervention, participants regained two-thirds of their prior weight loss.

In the STEP 1 trial extension, 327 participants who completed 68 weeks of once-weekly semaglutide 2.4 mg or placebo plus lifestyle intervention were followed for 52 weeks after discontinuing all treatments. Mean weight loss from week 0 to 68 was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following withdrawal, semaglutide participants regained 11.6 percentage points (SD: 7.7) of lost weight by week 120, yielding a net weight loss of 5.6% (SD: 8.9%) from week 0 to 120, while placebo participants regained 1.9 percentage points (SD: 4.8; net loss 0.1%). Cardiometabolic improvements seen at week 68 with semaglutide reverted toward baseline at week 120 for most variables.

Wilding JPH, Batterham RL, Davies M, et al. Diabetes Obes Metab, 2022. PMID 35441470

2022 / Uncontrolled interventional program evaluation

A 15-day whole-food plant-based program significantly reduced weight, blood pressure, cholesterol, LDL, and fasting blood sugar.

Participants enrolled in a 15-day Jumpstart program were instructed to consume an Esselstyn-compliant, whole-food plant-based diet of vegetables, fruits, whole grains, and legumes. Among 389 participants, average weight loss was 5.8 pounds (7.3 for BMI >30), systolic blood pressure dropped by 6.8 points (16.8 for baseline >140), cholesterol decreased by 26 points (44 for baseline >200), LDL dropped by 19 points (33 for baseline >100), and fasting blood sugar fell by 5.1 points (28.4 for those starting in the diabetic range). All reported comparisons achieved statistical significance (P < .005 for fasting blood sugar and P < .001 for all others).

Friedman SM, Barnett CH, Franki R, et al. Am J Lifestyle Med, 2022. PMID 35706593

2022 / Randomized controlled trial

At 5-year follow-up, differences in weight change between a commercial behavioural weight management programme and a brief intervention were not statistically significant.

The WRAP randomized controlled trial compared a brief intervention, a 12-week commercial open-group behavioural programme (WW), and a 52-week WW programme in adults with overweight and obesity. At 5 years, mean weight change from baseline was -0.46 kg (SD 8.31) for the brief intervention, -1.95 kg (9.55) for the 12-week group, and -2.67 kg (9.81) for the 52-week group. The adjusted difference in weight change was -1.76 kg (95% CI -3.68 to 0.17) between the 52-week programme and brief intervention, and -0.96 kg (-2.90 to 0.97) between the 12-week programme and brief intervention. Weight change differences between groups were not statistically significant, though simulations beyond 5 years suggested the 52-week programme would be the most cost-effective.

Ahern AL, Breeze P, Fusco F, et al. Lancet Public Health, 2022. PMID 36182236

2022 / Crossover trial

Substituting plant-based mince for beef mince reduced lunch pasta intake by 586 kJ without increasing subsequent buffet meal energy intake in healthy men.

In a crossover study, 24 healthy adult males consumed a pasta lunch with either plant-based or beef mince at separate visits. Participants consumed 586 kJ less of the plant-based mince pasta meal compared to the beef mince meal (p < 0.05). Energy intake at a subsequent buffet meal and ratings of fullness, satiety, and satisfaction were not different between meals (p > 0.05). Post-prandial GLP-1 concentrations were lower after the plant-based meal (p < 0.05), while insulin and leptin showed no differences.

Muhlhausler BS, Belobrajdic D, Wymond B, et al. Nutrients, 2022. PMID 36558487

1995 / Narrative review

Modest weight loss as low as 5% can reduce or eliminate disorders associated with obesity.

This review evaluates the effect of the degree of weight loss on specific disease states and risk factors. Evidence supports the value of a modest weight loss goal for health and emotional benefits, with losses as low as 5% reducing or eliminating obesity-related disorders. The paper also discusses how ethnic background, fat distribution, age, and mode of weight loss impact outcomes, while noting that several questions remain regarding these variables.

Blackburn G Obes Res, 1995. PMID 8581779

1995 / Narrative review

Excess visceral fat and hypercortisolism are linked to metabolic syndrome abnormalities and cardiocerebrovascular and diabetes risk.

This review discusses the relationship between hypercortisolism, stress axis activation, and obesity. Visceral fat is most strongly associated with morbidity and mortality from cardiocerebrovascular disease and diabetes, as well as metabolic syndrome (hypertension, hyperlipidemia, hyperinsulinemia, and insulin resistance). Metabolic syndrome is also present in Cushing's syndrome, characterized by primary hypercortisolism and profound visceral adiposity. Chronic physical or psychological stress impacts body composition through glucocorticoids, significantly affecting survival.

Shows an association, not proof of cause and effect.

Peeke PM, Chrousos GP Ann N Y Acad Sci, 1995. PMID 8597440

1993 / Narrative review of respiratory chamber studies

A review indicates fat-free mass accounts for 82% of RMR variance, with low metabolic rate serving as a major risk factor for weight gain.

This review summarizes data collected over 8 years measuring 24-h energy expenditure components in a respiratory chamber after a weight-maintenance diet in Pima Indians. Fat-free body mass explained 82% of the variance in resting metabolic rate (RMR), while an additional 7% was related to family membership. Low metabolic rate for a given body size was identified as a major risk factor for weight gain, with genetic factors implicated in the familial aggregation of metabolic rate.

Shows an association, not proof of cause and effect.

Ravussin E Diabetes Care, 1993. PMID 8422781

1989 / Narrative review

Avoiding excessive weight is supported for hypertension prevention, while sodium restriction evidence is less convincing and may be less practical.

This review examined evidence on whether reducing body weight and sodium intake can lower blood pressure and prevent hypertension. Evidence from cross-sectional, longitudinal, and intervention studies suggests hypertension can be prevented by avoiding excessive weight, especially in children and adolescents to prevent adult hypertension. In contrast, the hypothesis that sodium restriction reduces hypertension was viewed as less convincing, and the degree of restriction needed may make it less practical than weight loss.

Staessen J, Fagard R, Lijnen P, et al. J Hypertens Suppl, 1989. PMID 2651610

1989 / Narrative review

Upper-body obesity, commonly induced by caloric excess, is linked to hyperinsulinemia, hypertension, diabetes, and hypertriglyceridemia.

This review examines evidence on the role of upper-body obesity in mediating cardiovascular risk factors through hyperinsulinemia. Upper-body predominance of weight connects hypertension, diabetes, and hypertriglyceridemia, even without significant overall obesity. The author notes that caloric excess in the presence of androgens typically induces upper-body obesity, highlighting the need to prevent it or provide treatments that do not exacerbate hyperinsulinemia.

Kaplan NM Arch Intern Med, 1989. PMID 2662932

1985 / Narrative review

Evidence suggests there is no unique cancer malnutrition, with cachexia often resembling uncomplicated starvation or responses seen in major injury or sepsis.

This review examines the physiological interrelationships between nutrition and cancer. The authors note that data from experimental evidence, model systems, and nutritional manipulation suggest there is no unique cancer malnutrition, and early-diagnosed cancer does not present with malnutrition as a symptom. Metabolic disturbances are often proportional to tumor bulk, and cachexia in cancer patients largely resembles uncomplicated starvation or the features of major injury or sepsis unless the tumor burden is very large.

van Eys J Annu Rev Nutr, 1985. PMID 3927950

1985 / Review

Overweight individuals generally show no greater psychological disturbance than non-obese persons, despite facing widespread prejudice and discrimination.

Prejudice against obese persons is evident in children as young as 6 years old, alongside discrimination in academic and work settings. Despite this, overweight individuals in the general population and those seen for medical or surgical procedures generally show no greater psychological disturbance or psychopathology than non-obese individuals. Serious psychiatric disturbances linked to obesity include body image disparagement and negative emotional reactions to dieting, with dieting potentially contributing to increased bulimia incidence. Women, adolescent girls, and the morbidly obese appear to suffer the most deleterious consequences of societal contempt.

Wadden TA, Stunkard AJ Ann Intern Med, 1985. PMID 4062126